Cancer biomarker discovery for cholangiocarcinoma: The high-throughput approaches

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 6, 2014, Pages 388-396

  Silsirivanit, Atit ^a   Sawanyawisuth, Kanlayanee ^a,b   Riggins, Gregory J ^b   Wongkham, Chaisiri ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarkers Gene profiles Molecular signature Proteomics

Indexed keywords

CARBOHYDRATE BINDING PROTEIN; CORE PROTEIN; LECTIN; MOLECULAR MARKER; MONOCLONAL ANTIBODY; PROTEOME; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; CAPILLARY ELECTROPHORESIS; GLYCOBIOLOGY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SCREENING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; BILE DUCT NEOPLASMS; BLOOD; CHOLANGIOCARCINOMA; FEMALE; INTRAHEPATIC BILE DUCT; MALE; MASS SPECTROMETRY; PROCEDURES;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84901279436     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.68     Document Type: Article

References (50)

1. Blechacz B, Gores GJ,. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (Baltimore, Md.). 2008; 48: 308-321.
2. Rhea JM, Molinaro RJ,. Cancer biomarkers: surviving the journey from bench to bedside. MLO Med Lab Obs. 2011; 43: 10-12, 6, 8; quiz 20, 2.
3. Wongkham S, Silsirivanit A,. State of serum markers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev. 2012; 13 (Suppl): 17-27.
4. Darby IA, Vuillier-Devillers K, Pinault E, Sarrazy V, Lepreux S, Balabaud C, et al. Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. Cancer Microenviron. 2011; 4: 73-91.
5. Shi Y, Deng X, Zhan Q, Shen B, Jin X, Zhu Z, et al. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma. J Gastrointest Surg. 2013; 17: 1584-1591.
6. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003; 77: 245-252.
7. Chavez-Munoz C, Morse J, Kilani R, Ghahary A,. Primary human keratinocytes externalize stratifin protein via exosomes. J Cell Biochem. 2008; 104: 2165-2173.
8. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010; 9: 13.
9. Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, et al. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues. J Proteome Res. 2009; 8: 4092-4103.
10. 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res. 2008; 7: 4670-4677.
11. Dos Santos A, Court M, Thiers V, Sar S, Guettier C, Samuel D, et al. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol Cell Proteomics. 2010; 9: 1991-2004.
12. Yonglitthipagon P, Pairojkul C, Bhudhisawasdi V, Mulvenna J, Loukas A, Sripa B,. Proteomics-based identification of alpha-enolase as a potential prognostic marker in cholangiocarcinoma. Clin Biochem. 2012; 45: 827-834.
13. Yonglitthipagon P, Pairojkul C, Chamgramol Y, Loukas A, Mulvenna J, Bethony J, et al. Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol. 2012; 43: 1719-1730.
14. Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B,. Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 2010; 40: 1203-1212.
15. Srisomsap C, Sawangareetrakul P, Subhasitanont P, Panichakul T, Keeratichamroen S, Lirdprapamongkol K, et al. Proteomic analysis of cholangiocarcinoma cell line. Proteomics. 2004; 4: 1135-1144.
16. Srisomsap C, Subhasitanont P, Sawangareetrakul P, Chokchaichamnankit D, Ngiwsara L, Chiablaem K, et al. Comparison of membrane-associated proteins in human cholangiocarcinoma and hepatocellular carcinoma cell lines. Proteomics Clin Appl. 2007; 1: 89-106.
17. Srisomsap C, Sawangareetrakul P, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Bhudhisawasdi V, et al. Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol. 2010; 2010: 437143.
18. Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, et al. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem. 2008; 104: 745-755.
19. Wang X, Dai S, Zhang Z, Liu L, Wang J, Xiao X, et al. Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care (Engl). 2009; 18: 625-635.
20. Tolek A, Wongkham C, Proungvitaya S, Silsirivanit A, Roytrakul S, Khuntikeo N, et al. Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood). 2012; 237: 1142-1149.
21. Sriwanitchrak P, Viyanant V, Chaijaroenkul W, Srivatanakul P, Gram HR, Eursiddhichai V, et al. Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev. 2011; 12: 1503-1510.
22. Rucksaken R, Khoontawad J, Roytrakul S, Pinlaor P, Hiraku Y, Wongkham C, et al. Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer Biomark. 2012; 12: 81-95.
23. Alvaro D,. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009; 25: 279-284.
24. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, et al. A proteomic analysis of human bile. Mol Cell Proteomics. 2004; 3: 715-728.
25. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer. 2004; 101: 1609-1615.
26. Farid SG, Craven RA, Peng J, Bonney GK, Perkins DN, Selby PJ, et al. Shotgun proteomics of human bile in hilar cholangiocarcinoma. Proteomics. 2011; 11: 2134-2138.
27. Schenk S, Schoenhals GJ, de Souza G, Mann M,. A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics. 2008; 1: 41.
28. Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep. 2009; 22: 649-657.
29. Korita PV, Wakai T, Ajioka Y, Inoue M, Takamura M, Shirai Y, et al. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res. 2010; 30: 2279-2285.
30. Shen J, Wang W, Wu J, Feng B, Chen W, Wang M, et al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS ONE. 2012; 7: e47476.
31. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P,. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004; 65: 323-332.
32. Hortin GL, Sviridov D,. Diagnostic potential for urinary proteomics. Pharmacogenomics. 2007; 8: 237-255.
33. Metzger J, Negm AA, Plentz RR, Weismuller TJ, Wedemeyer J, Karlsen TH, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013; 62: 122-130.
34. Gomes AM, Stelling MP, Pavao MS,. Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed Res Int. 2013; 2013: 852093.
35. Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, et al. Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteomics Clin Appl. 2013; doi: 10.1002/prca.201200134.
36. Silsirivanit A, Araki N, Wongkham C, Vaeteewoottacharn K, Pairojkul C, Kuwahara K, et al. CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci. 2013; 104: 1278-1284.
37. Ben-David T, Sagi-Assif O, Meshel T, Lifshitz V, Yron I, Witz IP,. The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. Immunol Lett. 2008; 116: 218-224.
38. Renkonen J, Makitie A, Paavonen T, Renkonen R,. Sialyl-Lewis(x/a)- decorated selectin ligands in head and neck tumours. J Cancer Res Clin Oncol. 1999; 125: 569-576.
39. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T,. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res. 2008; 38: 1098-1111.
40. Matsuda A, Kuno A, Kawamoto T, Matsuzaki H, Irimura T, Ikehara Y, et al. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology. 2010; 52: 174-182.
41. Matsuda A, Kuno A, Matsuzaki H, Kawamoto T, Shikanai T, Nakanuma Y, et al. Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma. J Proteomics. 2013; 85: 1-11.
42. Indramanee S, Silsirivanit A, Pairojkul C, Wongkham C, Wongkham S,. Aberrant glycosylation in cholangiocarcinoma demonstrated by lectin-histochemistry. Asian Pac J Cancer Prev. 2012; 13 (Suppl): 119-124.
43. Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology. 2006; 44: 1025-1038.
44. Luengpailin S, Wongkham S, Wongkham C, Sripa B, Sirijaichingkul S, Chauin S, et al. Demonstration of a biliary-associated glycoprotein in human serum. Clin Chim Acta. 1996; 244: 237-240.
45. Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007; 247: 301-308.
46. Silsirivanit A, Araki N, Wongkham C, Pairojkul C, Narimatsu Y, Kuwahara K, et al. A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer. 2011; 117: 3393-3403.
47. Lv H, Yu G, Sun L, Zhang Z, Zhao X, Chai W,. Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology. 2007; 72: 347-356.
48. Batmunkh E, Tatrai P, Szabo E, Lodi C, Holczbauer A, Paska C, et al. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Hum Pathol. 2007; 38: 1508-1515.
49. Harada K, Masuda S, Hirano M, Nakanuma Y,. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 2003; 34: 857-863.
50. Sabit H, Tsuneyama K, Shimonishi T, Harada K, Cheng J, Ida H, et al. Enhanced expression of basement-membrane-type heparan sulfate proteoglycan in tumor fibro-myxoid stroma of intrahepatic cholangiocarcinoma. Pathol Int. 2001; 51: 248-256.